Immunotherapies – treatments that aim to make the body's natural immune system more effective – are becoming more widely used ...

Major histocompatibility complex class II (MHC II) molecules are central to adaptive immunity, presenting peptides derived from extracellular proteins to CD4+ T helper cells. Biosynthesis begins in ...

The expression of Major Histocompatibility Complex class II (MHC II) molecules on tumour cells has emerged as a critical determinant of antitumour immunity. Conventionally restricted to professional ...

Which came first, MHC class I or MHC class II? For decades, it has been debated which of these two similar classes came first in evolution. Now, Keiichiro Hashimoto and his group at Fujita Health ...

Disparities in trends in bladder cancer mortality between urban and rural patients: A 2000-2020 analysis. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not ...

The study, according to the researchers, is the first to demonstrate the potential use of major histocompatibility complex class II (MHC-II) expression as a predictor of immunotherapy response in ...

Cancer immunotherapy has transformed cancer treatment, yet many patients experience limited or short-lived responses due to immune evasion, tumor heterogeneity, and immune-related adverse events.

Major histocompatibility complex class II (MHC-II) molecules play a critical, yet historically overlooked, role in tumor immunity. This review synthesizes emerging mechanistic evidence showing that ...

Analysis of primary and acquired resistance to cetuximab from multiomic data in the New EPOC trial. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This abstract does not include ...